DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $374,879 | +4.0% | 1,511 | +0.6% | 0.07% | +7.4% |
Q2 2023 | $360,480 | -37.9% | 1,502 | -34.8% | 0.07% | -41.9% |
Q1 2023 | $580,196 | +6.4% | 2,302 | +12.1% | 0.12% | -0.8% |
Q4 2022 | $545,173 | -37.2% | 2,054 | -38.9% | 0.12% | -46.8% |
Q3 2022 | $868,000 | -1.4% | 3,361 | -3.2% | 0.22% | -1.8% |
Q2 2022 | $880,000 | -11.8% | 3,471 | +2.0% | 0.23% | -2.2% |
Q1 2022 | $998,000 | -20.0% | 3,403 | -10.2% | 0.23% | -19.2% |
Q4 2021 | $1,247,000 | +14.3% | 3,790 | +5.7% | 0.29% | -1.7% |
Q3 2021 | $1,091,000 | +17.9% | 3,584 | +4.0% | 0.29% | +16.9% |
Q2 2021 | $925,000 | +90.7% | 3,446 | +59.9% | 0.25% | +70.5% |
Q1 2021 | $485,000 | +18.0% | 2,155 | +16.5% | 0.15% | +9.0% |
Q4 2020 | $411,000 | +37.0% | 1,850 | +41.4% | 0.13% | +18.6% |
Q3 2020 | $300,000 | +35.1% | 1,308 | +4.0% | 0.11% | +25.6% |
Q2 2020 | $222,000 | +8.8% | 1,258 | +4.7% | 0.09% | 0.0% |
Q1 2020 | $204,000 | – | 1,201 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |